Delivery Order SPE2DB22D1017-SPE2DB25FG9EN
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,389.54 to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 6, 2025, with completion expected by August 7, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $22,972.76 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 14, 2025, with completion expected by August 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $38,528.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $25,169.28 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $11,671.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 16, 2025, with completion scheduled for July 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a $13,436.24 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed price contract with an ultimate completion date of September 18, 2025, and represents a non-set-aside procurement awarded competitively. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $29,308.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is a non-set-aside competitive award, carries an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9ENDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,242.03 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 ml pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. As a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, this award represents a specific pharmaceutical fulfillment to support military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, serves as a critical vendor for federal medical procurement through its DLA Troop Support Medical contract, which enables the company to supply a comprehensive range of brand-name and generic medications, vaccines, and medical devices to military healthcare programs worldwide. This delivery order for Dupixent, a biologic treatment used for conditions such as atopic dermatitis and moderate-to-severe asthma, exemplifies the contractor's role in supplying specialized pharmaceutical products across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 8/7/25 |